Mortality Down With GLP-1 Receptor Agonist Use in T2D, Especially in Those With OSA
Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA).
A study presented at the CHEST Annual Meeting 2025 found that GLP-1 RAs reduce mortality in patients with T2DM, particularly in those with OSA.
- The study examined data from the TriNetX U.S. Collaborative Network.
- A total of 1,799,261 patients with T2DM who were prescribed metformin were identified.
- Patients were stratified into groups, including those with T2DM without OSA prescribed metformin without GLP-1 RAs (60.2 percent) and those with T2DM without OSA prescribed metformin and GLP-1 RAs (20 percent).
According to the study, GLP-1 RAs significantly lower one-year mortality in patients with T2DM, especially those with OSA.
Author's summary: GLP-1 RAs reduce mortality in T2DM patients, especially those with OSA.